Therapeutic Neutrophil Apheresis in Patients With Ocular Behçet Disease

Granulocytapheresis in patients with refractory ocular Behcet's disease

“…Initially, we applied granulocytapheresis therapy to a small number of patients with ocular BD who responded with sustained improvements [18]. The outcome prompted us to undertake the present study in a larger cohort of patients with a major focus on background factors, which can determine response to granulocytapheresis.…”

“…In a preliminary study [18], we applied granulocytapheresis to a small number of cases with ocular BD who responded well and achieved sustained reduction in ocular attack. This study also sought to identify patients' background factors (if any), which could indicate response to this nonpharmacological therapy.…”

Granulocytapheresis in patients with refractory ocular Behcet's disease

“…Initially, we applied granulocytapheresis therapy to a small number of patients with ocular BD who responded with sustained improvements [18]. The outcome prompted us to undertake the present study in a larger cohort of patients with a major focus on background factors, which can determine response to granulocytapheresis.…”

“…In a preliminary study [18], we applied granulocytapheresis to a small number of cases with ocular BD who responded well and achieved sustained reduction in ocular attack. This study also sought to identify patients' background factors (if any), which could indicate response to this nonpharmacological therapy.…”

Immunopathogenesis of Ocular Behçet’s Disease

“…Fujimori et al [39] reported fluctuations in the apoptosis level of PMNs in accord with uveitic activity in BD patients and attributed this to impairment of the FasL-Fas interaction, which the authors suggested might explain the alternation between sudden inflammation attacks and self-limiting resolution in BU. In a small case series, absorptive neutrophil apheresis in refractory ocular BD patients reduced the frequencies of ocular attacks implying that neutrophil hyperactivity plays a role in the pathogenesis of BU [55]. …”

Clinical and immunological effects of adsorptive myeloid lineage leukocyte apheresis in patients with immune disorders

“…In the field of dermatology, the efficacy of GMA was first assessed in a patient with pyoderma gangrenosum (PG) with a remarkable but unexpected efficacy outcome . Following this observation, several authors have reported on the clinical efficacy of GMA for various skin disorders associated with RA, BD, generalized PP (GPP), PsA as well as IBD . In these studies, GMA with the Adacolumn has shown an excellent safety profile, and because of this feature, it is very much favored by the patients.…”

Granulocytapheresis in patients with refractory ocular Behcet's disease

“…Initially, we applied granulocytapheresis therapy to a small number of patients with ocular BD who responded with sustained improvements [18]. The outcome prompted us to undertake the present study in a larger cohort of patients with a major focus on background factors, which can determine response to granulocytapheresis.…”

“…In a preliminary study [18], we applied granulocytapheresis to a small number of cases with ocular BD who responded well and achieved sustained reduction in ocular attack. This study also sought to identify patients' background factors (if any), which could indicate response to this nonpharmacological therapy.…”

Immunopathogenesis of Ocular Behçet’s Disease

“…Fujimori et al [39] reported fluctuations in the apoptosis level of PMNs in accord with uveitic activity in BD patients and attributed this to impairment of the FasL-Fas interaction, which the authors suggested might explain the alternation between sudden inflammation attacks and self-limiting resolution in BU. In a small case series, absorptive neutrophil apheresis in refractory ocular BD patients reduced the frequencies of ocular attacks implying that neutrophil hyperactivity plays a role in the pathogenesis of BU [55]. …”

Clinical and immunological effects of adsorptive myeloid lineage leukocyte apheresis in patients with immune disorders

“…In the field of dermatology, the efficacy of GMA was first assessed in a patient with pyoderma gangrenosum (PG) with a remarkable but unexpected efficacy outcome . Following this observation, several authors have reported on the clinical efficacy of GMA for various skin disorders associated with RA, BD, generalized PP (GPP), PsA as well as IBD . In these studies, GMA with the Adacolumn has shown an excellent safety profile, and because of this feature, it is very much favored by the patients.…”

Granulocytapheresis in patients with refractory ocular Behcet's disease

“…Initially, we applied granulocytapheresis therapy to a small number of patients with ocular BD who responded with sustained improvements [18]. The outcome prompted us to undertake the present study in a larger cohort of patients with a major focus on background factors, which can determine response to granulocytapheresis.…”

“…In a preliminary study [18], we applied granulocytapheresis to a small number of cases with ocular BD who responded well and achieved sustained reduction in ocular attack. This study also sought to identify patients' background factors (if any), which could indicate response to this nonpharmacological therapy.…”

Immunopathogenesis of Ocular Behçet’s Disease

“…Fujimori et al [39] reported fluctuations in the apoptosis level of PMNs in accord with uveitic activity in BD patients and attributed this to impairment of the FasL-Fas interaction, which the authors suggested might explain the alternation between sudden inflammation attacks and self-limiting resolution in BU. In a small case series, absorptive neutrophil apheresis in refractory ocular BD patients reduced the frequencies of ocular attacks implying that neutrophil hyperactivity plays a role in the pathogenesis of BU [55]. …”

Clinical and immunological effects of adsorptive myeloid lineage leukocyte apheresis in patients with immune disorders

“…In the field of dermatology, the efficacy of GMA was first assessed in a patient with pyoderma gangrenosum (PG) with a remarkable but unexpected efficacy outcome . Following this observation, several authors have reported on the clinical efficacy of GMA for various skin disorders associated with RA, BD, generalized PP (GPP), PsA as well as IBD . In these studies, GMA with the Adacolumn has shown an excellent safety profile, and because of this feature, it is very much favored by the patients.…”